Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics

Core Insights - ERS Genomics and Dyadic Applied BioSolutions have entered into a CRISPR/Cas9 license agreement, allowing Dyadic to utilize ERS' extensive patent portfolio to enhance its bioproduction capabilities [1][2][3] Company Overview - ERS Genomics holds a portfolio of over 100 patents worldwide related to CRISPR/Cas9 technology, covering applications across various cell types and synthetic biology [3][6] - Dyadic Applied BioSolutions specializes in producing precision-engineered, animal-free proteins and enzymes for the life sciences, food and nutrition, and bio-industrial markets [5] Agreement Details - The agreement enables Dyadic to integrate CRISPR-based gene editing into its production platforms, specifically the C1 and Dapibus systems, to improve strain performance and product quality [2][3] - Financial details of the agreement have not been disclosed [4] Strategic Implications - The collaboration is expected to accelerate Dyadic's internal product pipeline and enhance the development of customized production strains for partners [2] - ERS Genomics emphasizes the importance of responsible use of CRISPR technology, aiming to support a wide range of applications in life sciences and bio-industrial sectors [2][3]